Key result
Breast cancer molecular subtypes show significant variation in baseline dyslipidemia prevalence averaging ~54% overall.
Why the study?
Cardiometabolic risk profiles present at breast cancer diagnosis remain incompletely characterized across molecular subtypes, and evidence from large real-world cohorts evaluating baseline dyslipidemia in treatment-naïve patients is limited.
What is the prevalence and pattern of dyslipidemia at diagnosis in women with newly diagnosed, treatment-naïve breast cancer?
Cohort (n=5,246)
What is the prevalence and pattern of dyslipidemia at diagnosis in women with newly diagnosed, treatment-naïve breast cancer?
More than half of women with newly diagnosed breast cancer present with dyslipidemia before any anticancer therapy, highlighting the need for early cardio-oncology risk stratification.
Answers are grounded in this paper and cite their sources.
May warrant early lipid assessment at breast cancer diagnosis; observational data leaves open subtype-specific cardio-oncology strategies.
e12692 Background: Cardiovascular disease has emerged as a major cause of long-term morbidity and mortality among breast cancer survivors. However, cardiometabolic risk profiles present at the time of breast cancer diagnosis—prior to any anticancer therapy—remain incompletely characterized, particularly across molecular subtypes. Evidence from large, real-world cohorts evaluating baseline dyslipidemia in treatment-naïve patients is limited. We aimed to characterize the prevalence and subtype-specific patterns of dyslipidemia at diagnosis in women with newly diagnosed breast cancer. Methods: We conducted a retrospective cohort study of 5,246 women with pathologically confirmed, treatment-naïve breast cancer diagnosed between 2014 and 2024. All clinical characteristics, laboratory measurements, and electrocardiographic data were collected at diagnosis before surgery or systemic therapy. Molecular subtypes were classified as Luminal A, Luminal B (HER2−), Luminal B (HER2+), HER2-enriched, and triple-negative breast cancer (TNBC) according to ASCO/CAP guidelines based on immunohistochemistry and in situ hybridization results. Dyslipidemia was defined as abnormal levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol, or triglycerides using guideline-based lipid thresholds. Subtype-specific comparisons were performed, and multivariable logistic regression analyses were used to identify factors associated with dyslipidemia. Results: Overall, 54.1% of patients exhibited dyslipidemia at diagnosis, with significant heterogeneity across molecular subtypes (P < 0.001). The prevalence was highest in Luminal A tumors (59.2%) and lowest in Luminal B (HER2−) tumors (43.9%). Elevated total cholesterol (29.5%) and triglycerides (25.7%) were the most common lipid abnormalities, while abnormalities in LDL-C and HDL-C demonstrated marked subtype-specific variation. Notably, patients with advanced-stage TNBC showed a particularly high prevalence of elevated LDL-C. In multivariable analyses, intravascular tumor thrombus was independently and consistently associated with dyslipidemia across all molecular subtypes (P < 0.001). Age and lymph node metastasis demonstrated subtype-dependent associations with dyslipidemia. Conclusions: More than half of women with newly diagnosed, treatment-naïve breast cancer present with dyslipidemia at diagnosis, with distinct patterns across molecular subtypes. These findings highlight the presence of clinically relevant cardiometabolic risk before initiation of anticancer therapy and support early lipid assessment as part of baseline cardio-oncology risk stratification. Incorporating lipid profiling at diagnosis may inform personalized survivorship planning, particularly for high-risk subtypes such as TNBC.
No takes yet. Share an insight, caveat, or question.
Xin et al. (2026) conducted a cohort in treatment-naïve breast cancer (n=5,246). Molecular subtypes of breast cancer demonstrated significant heterogeneity in baseline dyslipidemia prevalence, ranging from 43.9% in Luminal B (HER2-) to 59.2% in Luminal A.
Synapse has enriched 10 related papers. Consider them for comparative context: